Last reviewed · How we verify
Combination of pilocarpine 0.1% and phentolamine 0.75%
Combination of pilocarpine 0.1% and phentolamine 0.75% is a Small molecule drug developed by Mansoura University. It is currently in Phase 1 development.
At a glance
| Generic name | Combination of pilocarpine 0.1% and phentolamine 0.75% |
|---|---|
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of pilocarpine 0.1% and phentolamine 0.75% CI brief — competitive landscape report
- Combination of pilocarpine 0.1% and phentolamine 0.75% updates RSS · CI watch RSS
- Mansoura University portfolio CI
Frequently asked questions about Combination of pilocarpine 0.1% and phentolamine 0.75%
What is Combination of pilocarpine 0.1% and phentolamine 0.75%?
Combination of pilocarpine 0.1% and phentolamine 0.75% is a Small molecule drug developed by Mansoura University.
Who makes Combination of pilocarpine 0.1% and phentolamine 0.75%?
Combination of pilocarpine 0.1% and phentolamine 0.75% is developed by Mansoura University (see full Mansoura University pipeline at /company/mansoura-university).
What development phase is Combination of pilocarpine 0.1% and phentolamine 0.75% in?
Combination of pilocarpine 0.1% and phentolamine 0.75% is in Phase 1.